Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System
Authors' conclusion
e-AHCL was feasible. User satisfaction increased compared with earlier Medtronic HCL iterations without compromising glucose control.
Study context
- Population
- Adults with T1D; baseline HbA1c 6.7%/50 mmol/mol; 11 women21 completed
- Participants
- 22 adults
- Comparison
- e-AHCL vs run-in, stage 1 and stage 2
- Outcome
- Treatment satisfaction by Diabetes Technology Questionnaire (DTQ)-current score
Methodological detailsthree-stage (12 weeks each), run-in
- Three-stage (12 weeks each)
- Run-in
Main finding
As reported in the abstract
DTQ-current score
e-AHCL
123.1
unspecified (as printed) 17.8
Run-in
101.6
unspecified (as printed) 24.2
Stage 1
110.6
unspecified (as printed) 20.8
Stage 2
119.4
unspecified (as printed) 16.0
e-AHCL vs Run-in: P < 0.001 (both) · e-AHCL vs Stage 1: P < 0.001 (both) · e-AHCL vs Stage 2: P = 0.271
Further findings
| Outcome | Difference (%) | P value |
|---|---|---|
| Percent TIR 70-180 mg/dLe-AHCL vs Run-in · greater with e-AHCL | +2.9 | P < 0.001 (both) |
| Percent TIR 70-180 mg/dLe-AHCL vs Stage 2 · greater with e-AHCL | +3.6 | P < 0.001 (both) |
Diabetes Medication System Rating Questionnaire short-form "Convenience and Efficacy"
- Scores favored e-AHCL over run-in and all stages
Safety
| Outcome | Difference (%) | P value |
|---|---|---|
| Percent time <70 mg/dLe-AHCL vs Run-in | −0.9 | all P < 0.01 |
| Percent time <70 mg/dLe-AHCL vs Stage 1 | −0.6 | all P < 0.01 |
| Percent time <70 mg/dLe-AHCL vs Stage 2 | −0.5 | all P < 0.01 |
Original publication
Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System. Diabetes Care. Published 21 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →